Post by
Greenviolino on Oct 31, 2023 8:25pm
0.80 usd / 1.10 cad. Cash per share
And $80 million in sales. Potential for positive cash-flow depending on how fast Th spends on R&D. Legacy drugs allow them to manage burn rate. New institutional shareholders. Th has never been so cheap.
Comment by
jfm1330 on Nov 01, 2023 10:11am
The real picture is when you take into account the debt.
Comment by
houbahop on Nov 01, 2023 10:59am
May I add the real picture is when you take into account the people who drove the company where it stands, are all still well comfortably in place.
Comment by
Trogarzon on Nov 01, 2023 11:15am
You may and just secured their jobs with this massive dilution to top off the cash that coul'nt be remediated by a deal, an asset sale or any other less damaging option.
Comment by
Trogarzon on Nov 01, 2023 10:42am
The average Joe that's been invested since a decade are down on average 90% + and need a ten bagger just to brake even. Thats the legacy we have.
Comment by
scarlet1967 on Nov 01, 2023 7:41pm
"TH never been that cheap" Is that good or bad, reson for celebration or frustration?